Zacks Research Equities Analysts Increase Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) – Equities research analysts at Zacks Research increased their Q2 2024 EPS estimates for Apellis Pharmaceuticals in a report released on Monday, May 27th. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.36) per share for the quarter, up from their prior forecast of ($0.41). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.12) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.42) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.22 EPS, FY2025 earnings at $0.64 EPS and Q1 2026 earnings at $0.90 EPS.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. During the same quarter in the previous year, the business posted ($1.56) earnings per share. The business’s revenue was up 284.3% compared to the same quarter last year.

A number of other analysts have also issued reports on APLS. Robert W. Baird reissued an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. JPMorgan Chase & Co. boosted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday. Wells Fargo & Company lowered their price objective on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a research note on Thursday, May 23rd. Finally, Wedbush lowered their price objective on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $76.27.

Read Our Latest Stock Analysis on APLS

Apellis Pharmaceuticals Trading Up 1.4 %

APLS stock opened at $41.11 on Thursday. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The stock has a market capitalization of $4.99 billion, a price-to-earnings ratio of -11.92 and a beta of 0.97. The firm’s fifty day simple moving average is $49.18 and its two-hundred day simple moving average is $56.92.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock worth $572,003,000 after buying an additional 85,701 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Apellis Pharmaceuticals by 38.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after acquiring an additional 677,098 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Apellis Pharmaceuticals by 109.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after purchasing an additional 1,121,497 shares during the last quarter. Polar Capital Holdings Plc lifted its position in Apellis Pharmaceuticals by 126.6% during the third quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after purchasing an additional 588,875 shares during the period. Finally, Norges Bank purchased a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $56,640,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 6,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $63.22, for a total transaction of $379,320.00. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at $5,900,828.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Timothy Eugene Sullivan sold 6,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $63.22, for a total transaction of $379,320.00. Following the transaction, the chief financial officer now owns 93,338 shares in the company, valued at $5,900,828.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 250,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the transaction, the chief executive officer now owns 313,662 shares in the company, valued at approximately $20,108,870.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 448,012 shares of company stock valued at $26,015,139. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read More

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.